[Algorithms of mono- and polytherapy in clinical epileptology. Part 1. General principles of drug choice]

[Brivaracetam in the treatment of patients with epilepsy]

The newest antiepileptic drug (AED) brivaracetam (Briviac, UCB Pharma) (BRV) was approved in the Russian Federation in 2017 as an adjuvant therapy for the treatment of partial seizures with/without secondary generalization in adults and adolescents over 16 years old with epilepsy. This review contains the data of BRV preclinical studies, pharmacokinetic profile and the results of comparative study of BRV and LEV. The results of main studies of efficacy and tolerability with pooled analysis as well as data from meta-analysis are presented. The authors present conclusions of the Russian leading epileptologists on perspectives of using BRV in different populations of epileptic patients. The use of BRV is able to provide long-term efficacy in terms of seizure control, is well tolerated, keeps quality of life and social activity of people with epilepsy.

[Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders]

In this article, the results of personal prospective observation of lacosamide (LCM) administration in 91 adults with epilepsy and comorbid mental disorders are presented. LCM was administered as a part of polytherapy for 80 patients at a dose of up to 400 mg/day and of monotherapy for 11 patients at a dose of up to 600 mg/day for up to 12 months. Clinical-psychopathological and experimental-psychological monitoring of patients' condition over time was carried out using the Mental Health Comprehensive Assessment Scale (MHCAS), the Global Clinical Impression scale (GCI). As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration.